Biohaven Pharmaceutical Holding (BHVN) PT Raised to $46 at Canaccord Genuity
Tweet Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $46.00 (from $43.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
